单克隆抗体在整个妊娠期的药代动力学:系统文献综述
该系统综述检索PubMed和Embase至2023年4月21日,纳入42篇关于妊娠期单克隆抗体药代动力学或暴露参数的文章。除英夫利西单抗外,多数单克隆抗体血清浓度与孕前相似或仅轻度降低,而英夫利西单抗谷浓度在第二、三孕 trimester 较非妊娠状态普遍升高。结论提示妊娠期生理变化可能对单克隆抗体药代动力学产生有意义的影响,多数单克隆抗体(非英夫利西单抗)在妊娠期可能需要按每毫克适度增加剂量以维持与孕前相似的血清暴露。
要点
- 多数单克隆抗体妊娠期血清浓度与孕前相似或轻度降低。
- 英夫利西单抗谷浓度在第二、三孕 trimester 较非妊娠状态普遍升高。
- 除英夫利西单抗外,多数单克隆抗体妊娠期可能需按每毫克适度增加剂量。
核心结论
- 现有信息提示妊娠期解剖和生理变化可能对单克隆抗体的药代动力学产生有意义的影响。
- 对于大多数单克隆抗体(非英夫利西单抗),妊娠期可能需要按每毫克适度增加剂量以维持与孕前相似的血清暴露。
研究设计与样本
- 系统文献综述,检索PubMed和Embase截至2023年4月21日,纳入42篇提供妊娠期单克隆抗体药代动力学或暴露参数信息的文章。
主要发现
- 42篇文章中仅1篇报告了英夫利西单抗的清除率和分布容积,其余仅报告孕前、不同孕 trimester 和产后血清浓度。
- 除英夫利西单抗外,所有评估的单克隆抗体血清浓度与孕前相似或轻度降低。
- 英夫利西单抗谷浓度在第二、三孕 trimester 较非妊娠状态普遍升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Although little information is available on the pharmacokinetics (PK) of monoclonal antibodies (mAbs) during pregnancy, multiple mAbs are being used during pregnancy for various indications. The aim of this systematic literature review was to characterize the PK of mAbs throughout pregnancy. METHODS: A systematic literature search was carried out in PubMed and Embase on 21 April 2023. Articles were included when information on PK or exposure parameters of mAbs in pregnant women was available. RESULTS: A total of 42 relevant articles were included, of which eight discussed adalimumab, three certolizumab pegol, five eculizumab, one golimumab, 12 infliximab (IFX), two natalizumab, one canakinumab, one omalizumab, five tocilizumab, eight ustekinumab, and five vedolizumab. One of the 42 studies reported information on clearance (CL) and volume of distribution (VD) of IFX; all other studies only reported on serum concentrations in the pre-pregnancy state, different trimesters, and the postpartum period. For all of the assessed mAbs except IFX, serum concentrations were similar to concentrations in the pre-pregnancy state or modestly decreased. In contrast, IFX trough concentrations generally increased in the second and third trimesters in comparison to the non-pregnant state. CONCLUSION: Available information suggests that the anatomical and physiological changes throughout pregnancy may have meaningful effects on the PK of mAbs. For most mAbs (not IFX), modestly higher dosing (per mg) maybe needed during pregnancy to sustain a similar serum exposure compared to pre-pregnancy.
引用
- van Gendt J, Emaus R, Visschedijk MC, et al. Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review. Clin Pharmacokinet. 2024. PMID: 38583128. doi:10.1007/s40262-024-01370-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。